Physicians' Academy for Cardiovascular Education

No clinical benefit of potent P2Y12 inhibitor over clopidogrel in peripheral artery disease

3' education - Jan. 4, 2017 - AHA 2016, New Orleans, LA, USA - Prof. Freek Verheugt, Amsterdam, The Netherlands

Educational information

Prof. Verheugt summarises the important but neutral findings of the EUCLID trial, in which over 13000 patients with peripheral artery disease were randomised to monotherapy with either clopidogrel or ticagrelor. No difference in effect was seen on the incidence of death, myocardial infarction and stroke. Nor was a difference seen in the incidence of bleedings.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: